Functional Brands nine-month loss widens to $10.3M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Functional Brands Inc. (MEHA) reported nine-month revenue of $5,161,125, compared with $5,116,963 a year earlier, while net loss widened to $10,335,792 from $93,837. Operating activities used $1,018,212 of cash, versus providing $1,478,358; cash was $231,900 and the working capital deficit was $5,804,557 at September 30, 2026.
The company ceased HT Naturals and its hemp-based consumer products business on March 31, leaving the Kirkman business as its continuing operation. Failure to begin Series C mandatory redemptions and the June 16 Nasdaq delisting triggered defaults under Series C and senior secured convertible notes. The Series C stated value of $2,764,000 remains subject to redemption; default terms include 24% annual Series C dividends and note interest, note obligations at 125% of otherwise outstanding amounts, and a $5,000 monthly monitoring fee. No holder had accelerated as of the report date. Management says substantial doubt about continuing as a going concern remains and concluded its plans were not probable of effective implementation or mitigation. BullionFX terminated a proposed acquisition with expected consideration of approximately $142.9 million in preferred stock, subject to valuation and verification.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointSubstantial doubt remains; September 30 cash was $231,900.
- Major pointDefaults impose 24% rates, 125% note obligations and $5,000 monthly fees.
- Major pointNet loss reached $10,335,792, versus $93,837 in 2025.
- Major pointNasdaq delisting shifted MEHA common-stock trading to OTC on June 16, 2026.
- Moderate pointOperating cash flow was $1,018,212 used, versus $1,478,358 provided.
Filing Explained
At September 30, 2026, common shares outstanding were 64,921,095, and default conversion pricing was tied to a recent trading low.
At
The
After default, the Series C and notes’ conversion price became
Key Figures
Key Terms
going concern financial
mandatory redemption financial
Event of Default financial
default premium financial
alternate conversion price financial
Level 3 technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue and net loss did MEHA report for the first nine months of 2026?
What default terms apply to MEHA’s Series C and convertible notes?
Did MEHA complete the proposed BullionFX asset acquisition?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
FOR THE QUARTERLY
PERIOD ENDED
OR
Commission File
Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) | |
| (Address of principal executive offices) | (Zip Code) |
| (Registrant’s telephone number, including area code) |
| NONE |
| (Former name or former address, if changed since last report.) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange On Which Registered | ||
| OTC Markets |
Indicate by checkmark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer ☐ | Accelerated Filer ☐ | Smaller Reporting Company |
|
| Emerging Growth Company |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by checkmark whether the registrant
is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No
The number of shares of registrant’s common
stock outstanding as of November 13, 2026:
FUNCTIONAL BRANDS INC.
TABLE OF CONTENTS
| Page No. | |||
| PART I. | FINANCIAL INFORMATION | 1 | |
| Item 1. | Consolidate Financial Statements (Unaudited) | 1 | |
| Unaudited Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 | 1 | ||
| Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 | 2 | ||
| Unaudited Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 | 3 | ||
| Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 | 5 | ||
| Notes to Unaudited Consolidated Financial Statements | 6 | ||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 27 | |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 37 | |
| Item 4. | Controls and Procedures | 37 | |
| PART II. | OTHER INFORMATION | 38 | |
| Item 1. | Legal Proceedings | 38 | |
| Item 1A. | Risk Factors | 38 | |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 39 | |
| Item 3. | Defaults Upon Senior Securities | 39 | |
| Item 4. | Mine Safety Disclosures | 39 | |
| Item 5. | Other Information | 39 | |
| Item 6. | Exhibits | 40 | |
| PART III. | Signatures | 41 |
i
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
FUNCTIONAL BRANDS INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In U.S. dollars, except share data or otherwise noted)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventories, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Noncurrent assets: | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ equity / (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | $ | ||||||
| Line of credit | - | |||||||
| SBA loan, current | ||||||||
| Lease liabilities, current | ||||||||
| Other current liabilities | ||||||||
| Loans payable (related party), current | ||||||||
| Loans payable | ||||||||
| Convertible note | - | |||||||
| Derivative liabilities | ||||||||
| Preferred shares liabilities | - | |||||||
| Total current liabilities | ||||||||
| Non-current liabilities: | ||||||||
| Lease liabilities, net of current | ||||||||
| SBA loan, net of current | ||||||||
| Loan payable (related party), net of current | ||||||||
| Total non-current liabilities | ||||||||
| Total liabilities | ||||||||
| Stockholders’ equity / (deficit) | ||||||||
| Series A Preferred stock, par value $ |
- | |||||||
| Series B Preferred stock, par value $ |
- | |||||||
| Series C Preferred stock, par value $ |
- | - | ||||||
| Common stock, $ |
||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( |
) | ( |
) | ||||
| Total stockholders’ equity / (deficit) | ( |
) | ||||||
| Total liabilities and stockholders’ equity / (deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
1
FUNCTIONAL BRANDS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In U.S. dollars, except share data or otherwise noted)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue, net of returns | ||||||||||||||||
| Cost of goods sold | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Other income / (expense) | ||||||||||||||||
| Interest income | ||||||||||||||||
| Other income | - | - | ||||||||||||||
| Other income – ERTC refund | - | - | ||||||||||||||
| Interest expense | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Other expenses | - | ( |
) | |||||||||||||
| Change in fair value of derivative liabilities | ( |
) | - | ( |
) | - | ||||||||||
| Loss on issuance of preferred stock | - | - | ( |
) | - | |||||||||||
| Loss on default | - | - | ( |
) | - | |||||||||||
| Total other income / (expense) | ( |
) | ( |
) | ||||||||||||
| Net loss | $ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
| Net loss per share of common stock attributable to common stockholders | ||||||||||||||||
| Basic | $ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
| Diluted | $ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
| Weighted average shares used in computing net loss per share of common stock | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
2
FUNCTIONAL BRANDS INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY / (DEFICIT) (UNAUDITED)
(In U.S. dollars, except share data or otherwise noted)
For the Three Months Ended September 30, 2025
| Preferred Stock | Common Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | to be issued | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | APIC | Deficit | Equity | ||||||||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2025 | - | $ | - | - | $ | - | - | $ | - | $ | - | $ | - | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Shares issued for financing | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | - | $ | - | - | $ | - | - | $ | - | $ | - | $ | - | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||||||||||
For the Three Months Ended September 30, 2026
| Preferred Stock | Common Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | to be issued | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | APIC | Deficit | Equity / (Deficit) | ||||||||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2026 | - | $ | - | - | $ | - | $ | - | $ | - | $ | - | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||||
| Conversion of preferred stock | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Buyback of preferred stock | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Shares issued as part of exchange agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Warrant exercises | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Preferred stock dividends | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Conversion of convertible notes | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2026 | - | $ | - | - | $ | - | $ | - | $ | - | $ | - | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||||
3
For the Nine Months Ended September 30, 2025
| Preferred Stock | Common Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | to be issued | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | APIC | Deficit | Equity | ||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2024 | - | $ | - | - | $ | - | $ | - | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for convertible notes payable and accrued interest | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Warrants issued with respect of loan payable | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of shares to debenture holder | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Shares issued for note extension | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | - | $ | - | - | $ | - | - | $ | - | $ | - | - | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||
For the Nine Months Ended September 30, 2026
| Preferred Stock | Common Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | to be issued | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | APIC | Deficit | Equity / (Deficit) | ||||||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2025 | $ | $ | - | $ | - | $ | $ | - | $ | - | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||
| Conversion of preferred stock | - | - | ( |
) | ( |
) | ( |
) | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Buyback of preferred stock | ( |
) | ( |
) | - | - | - | - | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Shares issued as part of exchange agreement | ( |
) | ( |
) | ( |
) | ( |
) | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Warrant exercises | - | - | - | - | - | - | - | - | ( |
) | - | |||||||||||||||||||||||||||||||||||||||||
| Preferred stock dividends | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
| Conversion of convertible notes | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2026 | - | $ | - | - | $ | - | $ | - | $ | - | $ | - | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
4
FUNCTIONAL BRANDS INC.
CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)
(In U.S. dollars, except share data or otherwise noted)
| Nine Months Ended | ||||||||
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( |
) | $ | ( |
) | ||
| Reconcile net loss to cash provided by operating activities | ||||||||
| Allowance for doubtful accounts receivable | - | ( |
) | |||||
| Allowance for inventory obsolescence | ( |
) | ||||||
| Depreciation of property and equipment | ||||||||
| Amortization of right-of-use assets | ||||||||
| Amortization of intangible assets | ||||||||
| Stock-based compensation | ||||||||
| Issuance of shares to debenture holder | - | |||||||
| Issuance of warrants | - | |||||||
| Change in fair value of derivative liabilities | - | |||||||
| Loss on issuance of convertible note | - | |||||||
| Loss on issuance of preferred stock | - | |||||||
| Dividends | ( |
) | - | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Inventories | ( |
) | ||||||
| Prepaid expenses and other current assets | ||||||||
| Accounts payable and accrued liabilities | ||||||||
| Other current liabilities | ( |
) | ||||||
| Lease liabilities | ( |
) | ( |
) | ||||
| Net cash (used in) provided by operating activities | ( |
) | ||||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | - | ( |
) | |||||
| Net cash provided by (used in) investing activities | - | ( |
) | |||||
| Cash flows from financing activities: | ||||||||
| Deferred offering costs | - | ( |
) | |||||
| Dividends paid | ( |
) | - | |||||
| Proceeds from loans | ||||||||
| Payments for payable for acquisition | - | ( |
) | |||||
| Repayment of liability conditional timing | ( |
) | - | |||||
| Repayment of loans | ( |
) | ( |
) | ||||
| Buyback of preferred stock | ( |
) | - | |||||
| Proceeds from line of credit | - | |||||||
| Line of credit repayment | ( |
) | ( |
) | ||||
| SBA loan repayment | ( |
) | ( |
) | ||||
| Net cash used in financing activities | ( |
) | ( |
) | ||||
| Increase (decrease) in cash | ( |
) | ||||||
| Cash beginning of period | ||||||||
| Cash, end of period | $ | $ | ||||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Non-cash investing and financing activities | ||||||||
| Common stock issued for convertible note payable and accrued interest | - | $ | ||||||
| Loan payable, related party | - | $ | ||||||
| Derecognition of derivative liabilities upon extinguishment of Series A&B preferred shares | $ | ( |
) | $ | - | |||
| Extinguishment of Series A&B preferred shares | $ | ( |
) | $ | - | |||
| Issuance of Series C preferred shares | $ | ( |
) | $ | - | |||
| Recognition of derivative liabilities upon issuance of Series C preferred shares & convertible notes | $ | ( |
) | $ | - | |||
| Recognition of Series C convertible notes | $ | ( |
) | $ | - | |||
| Warrant exercise | $ | $ | - | |||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
5
FUNCTIONAL BRANDS INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
| 1. | Organization and Nature of Operations |
Functional Brands Inc. (formerly HT Naturals
Inc., the “Company”) was organized under the General Corporation Law in the State of Delaware on
On March 22, 2023, the Company changed its name from HT Naturals Inc. to Functional Brands Inc. to better reflect its corporate identity.
As of September 30, 2026, and 2025, the consolidated financial statements consist of the Company and its wholly owned subsidiary HTO Nevada Inc. (d/b/a Kirkman), which is a nutraceutical manufacturer and distributor based in the Pacific Northwest. All intercompany transactions and balances have been eliminated in consolidation.
| 2. | Summary of Significant Accounting Policies |
Going Concern
The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern. For the nine months ended September 30, 2026, the Company had
net loss of $
In addition, the Company is in default under
its Series C Convertible Preferred Shares and its Senior Secured Convertible Notes as a result of its failure to commence the Series C
mandatory redemption (effective June 8, 2026) and the delisting of its common stock from the Nasdaq Capital Market (effective June 16,
2026). As a result, the holders have the right to accelerate the Notes, the Notes have been classified as current liabilities, default-rate
interest and a default premium apply, and the outstanding Series C stated value of $
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management is in discussions with the holders and is evaluating alternatives, which may include waivers, forbearance, amendments, restructuring or refinancing of the instruments, and additional equity or debt financing. Because none of these plans had been finalized or approved as of the date these consolidated financial statements were issued, and their implementation depends on parties outside the Company’s control, management has concluded that it is not probable that the plans will be effectively implemented or will mitigate the relevant conditions. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued has not been alleviated. There can be no assurance that any of these alternatives will be available on acceptable terms, or at all.
In order to continue as a going concern, the Company will need, among other things, additional capital resources. The Company is significantly dependent upon its ability to secure additional equity and/or debt financing. There are no assurances that the Company will be successful in obtaining additional capital.
The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
6
Unaudited Financial Information
The Company’s unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments, consisting of a normal recurring nature, considered necessary for a fair statement of the Company’s financial condition and results of operations. Operating results for the periods presented are not necessarily indicative of the results that might be expected for the full year. As such, the information included in this report should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025, which are included in the Company’s Form 10-K, dated and filed with the SEC on March 27, 2026, which is accessible on the SEC’s website at www.sec.gov.
During the nine months ended September 30, 2026, there were no changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025.
Principles of Consolidation
The financial statements of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies.
Functional Brands Inc. (formerly HT Naturals Inc.)
| ● | Functional Brands Inc. (formerly HT Naturals Inc.) is the parent company. |
HTO Nevada Inc. dba Kirkman
| ● | HTO Nevada Inc. dba Kirkman, which is owned by the Company is the sole subsidiary. |
As part of the restructuring efforts, ownership
of HTO Nevada Inc. dba Kirkman was transferred from HTO Holdings Inc. to Functional Brands Inc. (formerly HT Naturals Inc.) on May 19,
2023, in exchange for
Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net income or stockholders’ equity.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and be based on events different from those assumptions. Future events and their effects cannot be predicted with certainty; estimating, therefore, requires the exercise of judgment. Thus, accounting estimates change as new events occur, as more experience is acquired, or as additional information is obtained.
Cash
Cash consists of cash in readily available checking
accounts and deposits in transit. As of September 30, 2026 and December 31, 2025, cash balances were deposited at major and other financial
institutions. On September 30, 2026 and December 31, 2025, the Company had $
7
Accounts Receivable, net
Accounts receivable consists of trade receivables arising from contracts with customers, are recorded at the invoiced amount, and do not bear interest. The Company maintains an allowance for credit losses in accordance with ASC 326, Financial Instruments – Credit Losses, representing management’s estimate of expected credit losses over the contractual life of the receivables. Receivables with similar risk characteristics are evaluated on a pooled basis using historical collection experience, the aging of balances, and the financial condition of customers, adjusted for current conditions and reasonable and supportable forecasts. Receivables that do not share similar risk characteristics are evaluated individually. Balances are written off against the allowance when collection efforts have been exhausted and recovery is considered remote.
Inventories
Inventory consists of raw materials, packaging supplies and finished goods. Inventory is measured at the lower of cost or net realizable value. Inventory costs include direct labor and certain overhead expenses such as in-bound shipping and handling costs incurred to bring the inventory to its present location and conditions. Cost is determined by using the weighted average method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. If the Company determines that the estimated net realizable value of its inventory is less than the carrying value of such inventory, it records a charge to impairment expenses.
As of September 30, 2026 and December 31, 2025 there was no impairment to the Company’s net realizable value of its inventory.
Property and Equipment
Property and equipment are stated at cost. Depreciation of property and equipment is recorded using the straight-line method over the assets’ estimated useful lives. Amortization of fixed assets under capital leases is included in depreciation expense.
The categories of capital assets are amortized on a straight-line basis as follows:
| ● | Machinery and equipment |
| ● | Furniture and fixtures |
| ● | Computer equipment |
The Company allocates the amount initially recognized for a capital asset to its significant parts and amortizes separately each part. Residual values, methods of amortization and useful lives of the capital assets are reviewed annually and adjusted if appropriate.
The assets’ residual values, useful lives and methods of depreciation are reviewed at each fiscal year-end and adjusted prospectively if appropriate. An item of equipment is retired upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on sale or retirement of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the consolidated statement of operations in the year the asset is retired. Such assets are tested annually for impairment, or more frequently, if events or changes in circumstances indicate that they might be impaired.
8
Intangible Assets
Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.
The categories of the intangible assets are amortized on a straight-line basis as follows:
| ● | Customer relationships |
| ● | cGMP certification |
| ● | Goodwill (including Assembled Workforce) |
| ● | Kirkman brand |
Expenditures in the research phase and post-development maintenance costs are expensed as incurred.
Goodwill
Goodwill arises from business combinations and is generally determined as the excess of the fair value of the consideration transferred, plus the fair value of any non-controlling interests in the acquire, over the fair value of the net assets acquired and liabilities assumed as of the acquisition date. Goodwill acquired in a business combination is not amortized but tested for impairment at least annually or more frequently if events and circumstances exist that indicate that a goodwill impairment test should be performed.
Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment or one level below an operating segment (referred to as a component). The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. Assets and liabilities are assigned to each reporting unit if they are employed by a reporting unit and are considered in the determination of the reporting unit fair value. The Company has one reporting unit with goodwill, which is the Kirkman business.
The Company’s indefinite-lived intangible assets are tested for impairment at the consolidated level. In evaluating the recoverability of the Kirkman brand name and Current Good Manufacturing Practice (“cGMP”) certification which refers to U.S. Food and Drug Administration (“FDA”) regulations ensuring that food, drug, and medical device manufacturers maintain high standards for safety, quality, and purity through proper design, monitoring, and control of manufacturing processes and facilities. The Company compared the fair value of the asset to its carrying amount to determine potential impairment. The Company’s estimate of the fair value of the Kirkman brand name is derived using the income approach, specifically the relief-from-royalty method and the fair value of the cGMP certification is derived using the income approach.
The fair value determination of the reporting units and the indefinite-lived intangible asset is judgmental in nature and requires the use of significant estimates and assumptions that are sensitive to changes. Assumptions include estimation of the royalty rate, estimation of future revenue and projected margins, which are dependent on internal cash flow forecasts, estimation of the terminal growth rates and capital spending, and determination of discount rates. As a result, there can be no assurance that the estimates and assumptions made for purposes of quantitative goodwill and indefinite-lived intangible impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of the reporting units may include such items as: (i) volatility in the equity and debt markets or other macroeconomic factors, (ii) an increase in the weighted-average cost of capital due to further increases in interest rates, (iii) decrease in future cash flows due to lower than expected sales, or (iv) fluctuations in foreign currency exchange rates that may negatively impact the Company’s reported results of operations. Accordingly, if the current cash flow assumptions are not realized, we experience further increases in costs of capital, it is possible that an additional impairment charge may be recorded in the future, which could be material.
9
Right-of-Use Assets and Lease Liabilities
The Company accounts for leases in accordance with ASC 842, Leases. At the commencement date of a lease, the Company recognizes a right-of-use (“ROU”) asset and a corresponding lease liability, measured at the present value of the lease payments over the lease term. The Company discounts lease payments using the rate implicit in the lease, if readily determinable, and otherwise its incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has made an accounting policy election not to recognize lease assets or liabilities for leases with a term of 12 months or less. Assets under finance leases are included in property and equipment and depreciated over the useful life of the underlying asset, as the Company expects to exercise the related purchase options.
Derivative Liabilities
The Company’s accounting for the Series A, Series B and Series C Convertible Preferred Stock, the Senior Secured Convertible Promissory Notes and the related embedded derivative liabilities is described in Notes 15, 16 and 18.
Stock-Based Compensation Plan
The Board of Directors has authorized with shareholder’s approved the 2026 Equity Incentive Plan that may be used to compensate or reward the members of its board of directors, executive officers, employees and consultants for services rendered.
No expense is recognized for performance-based awards that do not vest. Expense for service-based award is recognized upon receipt of the agreed upon services. Where the terms of an equity settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified. An additional expense is recognized for any modification which increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification.
Compensation expense is recognized for all share-based payments to employees and non-employees, including restricted stock units and options “instruments” in the statements of operation based on the fair value of the awards that are granted. As necessary, the Company’s stock price at the date of grant was estimated using an acceptable valuation technique such as a recent round of fundraising or the probability-weighted expected return model. The fair value of instruments granted before the Nasdaq public listing was assessed at the grant date, using the share price established in the most recent 409a valuation report conducted by an external appraiser. For future RSU grants, fair value will be based on the Company’s stock price at the time of issuance.
Compensation expense for restricted stock awards with performance-based vesting conditions is calculated based on the number of awards that are expected to vest during the performance period if it is probable that the performance metrics will be achieved. Generally, measured compensation cost, net of actual forfeitures, is recognized on a straight-line basis over the vesting period of the related share-based compensation award. The Company accounts for forfeitures of stock-based awards as they occur.
Revenue Recognition
The Company accounts for revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers”. Revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers is recognized at the time the related merchandise revenues are recognized and are included in net revenues.
Per Company policy, any product that does not meet the customer’s expectations can be returned within 30 days of delivery in exchange for another product, or for a full refund. Any product sold through a distributor or retailer must be returned to the original purchase location for any return or exchange. For the nine months ended September 30, 2026 and 2025, the Company did not record any reserves on revenue for product returns or exchanges.
10
Earnings / (Loss) per Share
Basic earnings / (loss) per common share is calculated by dividing the net income (loss) distributed to the common class minus the preferred stock dividends, by the weighted-average number of shares outstanding during the period, without consideration for potentially dilutive securities. Diluted earnings (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares and potentially dilutive securities outstanding for the period.
For purposes of the diluted net loss per share calculation, restricted stock units (RSUs), outstanding warrants, conversion of Series B and Series C Preferred stock, and conversion of convertible notes. are considered to be potentially dilutive securities.
As of September 30, 2026,
As of September 30, 2025, there were
The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings (loss) per share (“EPS”) calculations for the three and nine months ended September 30, 2026 and 2025.
| 9 Months Ending | 3 Months Ending | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net loss /income | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
| Dividends | ( |
) | - | ( |
) | - | ||||||||||
| Total Numerator | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
| Denominator: | ||||||||||||||||
| Weighted-average shares of common stock | ||||||||||||||||
| Dilutive effect of RSU’s | - | - | - | |||||||||||||
| Dilutive effect of Warrants | - | - | - | |||||||||||||
| Diluted weighted average of common stock | ||||||||||||||||
| Net loss per common share from: | ||||||||||||||||
| Basic | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
| Diluted | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
Risks and Uncertainties
The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. Several factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include but are not limited to, general consumer demand, and new regulations imposed by the FDA. These adverse conditions could affect the Company’s consolidated financial condition and the results of its operations.
11
| 3. | Cash |
Cash consists of liquid funds and deposits in transit.
| September 30, 2026 |
December 31, 2025 |
|||||||
| Cash | $ | $ | ||||||
| Deposits in transit | ||||||||
| Total Cash | $ | $ | ||||||
| 4. | Accounts Receivable |
Accounts receivable consists of trade receivables, net of allowance for doubtful accounts.
| September 30, 2026 |
December 31, 2025 |
|||||||
| Accounts receivable | $ | $ | ||||||
| Allowance for doubtful accounts | - | - | ||||||
| Accounts receivable, net | $ | $ | ||||||
As of September 30, 2026 and December 31, 2025,
management determined that expected credit losses were not material and that no
allowance for credit losses was required. In making this determination, management considered the Company’s historical loss experience,
which has been minimal; the aging of outstanding balances, of which approximately
| 5. | Inventories |
Inventories consisted of raw materials (minerals – magnesium, calcium, vitamins, botanical extracts), finished goods (capsules, tablets, powders, and creams) and packaging and supplies (bottles, labels, covers, filters, tipping paper and packaging materials).
| September 30, 2026 |
December 31, 2025 |
|||||||
| Raw materials | $ | $ | ||||||
| Packaging, supplies & other | ||||||||
| Finished goods | ||||||||
| Allowance for inventory obsolescence | ( |
) | ( |
) | ||||
| Total inventories, net | $ | $ | ||||||
The Company reviews the allowance for inventory obsolescence on a quarterly basis and adjusted as necessary.
12
| 6. | Prepaid Expenses and Other Current Assets |
| September 30, 2026 |
December 31, 2025 |
|||||||
| Prepaids & deposits | $ | $ | ||||||
| Other current assets | - | |||||||
| Total prepaids and other current assets | $ | $ | ||||||
Prepaid expenses consist of prepayments made to vendors as deposit and or retainers for professional services and insurance, and other current assets consists of refunds owed on insurance policies as well as reimbursement for professional fees.
| 7. | Property and Equipment |
Property and equipment consist of the following: The machinery and equipment owned by Kirkman allows the Company to carry out the entire production process in-house, from mixing raw materials to creating finished products, including encapsulation, labeling, and packaging.
| September 30, 2026 |
December 31, 2025 |
|||||||
| Machinery & Equipment | $ | $ | ||||||
| Computer Equipment | ||||||||
| Furniture & Fixtures | ||||||||
| Total property and equipment | ||||||||
| Less: Accumulated depreciation | ( |
) | ( |
) | ||||
| Property and equipment, net | $ | $ | ||||||
Depreciation expense totaled $
Depreciation expense totaled $
| 8. | Right-of-Use Assets and Lease Liabilities |
The Company maintains leases on a building and certain business equipment as detailed below. These obligations include the minimum lease payments as recognized on a straight-line basis over the lease term. The following are the expected payments on these leases as of September 30, 2026. The leases are considered “operating lease” and consequently lease payments are calculated on a straight-line basis, including the total amount of interest related.
The changes in the right-of-use assets are as follows:
| September 30, 2026 |
December 31, 2025 |
|||||||
| Right of use assets: | ||||||||
| Right of use assets recognized as of January 1st | $ | $ | ||||||
| Additions | - | - | ||||||
| Amortization Expense | ( |
) | ( |
) | ||||
| Right of use assets, net | $ | $ | ||||||
13
The changes in lease liabilities are as follows:
| September 30, 2026 |
December 31, 2025 |
|||||||
| Lease liabilities recognized as of January 1st | $ | $ | ||||||
| Additions | - | - | ||||||
| Lease payments | ( |
) | ( |
) | ||||
| Lease liabilities at period end | ||||||||
| Less: current portion | ( |
) | ( |
) | ||||
| Long-term portion | $ | $ | ||||||
The following table presents information about the future maturity of the lease liabilities under the Company’s operating and financing leases as of September 30, 2026.
| Maturity of Lease Liabilities | 1. Operating Facility | 2. Office Equipment | 3. Office Equipment | Total Amount |
||||||||||||
| 2026 | $ | $ | $ | $ | ||||||||||||
| 2027 | - | - | ||||||||||||||
| 2028 | - | - | ||||||||||||||
| 2029 | - | - | ||||||||||||||
| 2030 | - | - | ||||||||||||||
| Total future minimum lease payments | ||||||||||||||||
| Less: Imputed interest | ( |
) | - | - | ( |
) | ||||||||||
| Present value of lease liabilities | $ | $ | $ | $ | ||||||||||||
| Remaining lease term (in years) | ||||||||||||||||
Right-of-use assets and lease liabilities comprise three leases.
Lease 1, Operating Facility
On January 1, 2023, the Company entered into
a
The base monthly rent is $
Leases 2 and 3, Equipment
Leases 2 and 3 are office equipment leases:
four copiers under a
14
| 9. | Intangible Assets and Goodwill |
On July 3, 2019, the Company entered into an
Asset Purchase Agreement (the “APA”) with the Kirkman Group Inc. and David Humphrey (collectively, “Kirkman”)
to acquire certain tangible and intangible assets for a purchase price of $
The excess of purchase consideration over the fair value of net assets acquired was recorded as goodwill.
The Kirkman brand and the cGMP certification
were assigned an indefinite useful life, whereas the customer relationships were assigned a life span of
The following table summarizes the remaining fair value of assets acquired and liabilities assumed from the acquisition of Kirkman in July 2019.
| September 30, 2026 |
December 31, 2025 |
|||||||
| Kirkman brand, net | $ | $ | ||||||
| cGMP certification | ||||||||
| Customer relationships | ||||||||
| Total intangible assets, gross | ||||||||
| Less: Accumulated amortization: Customer relationships | ( |
) | ( |
) | ||||
| Intangible assets, net | $ | $ | ||||||
The following table presents the amortization for the remaining useful life of the customer relationships:
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Total | $ |
Goodwill
| September 30, 2026 |
December 31, 2025 |
|||||||
| $ | $ | |||||||
Impairment Assessment
Goodwill and indefinite-lived intangible assets are tested for impairment annually as of December 31, and between annual tests when events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Customer relationships, a finite-lived intangible asset, are tested for recoverability when events or changes in circumstances indicate that the carrying amount may not be recoverable.
During the nine months ended September 30, 2026, management identified the following as indicators of potential impairment: the decline in the Company’s share price and market capitalization; the delisting of its common stock from the Nasdaq Capital Market in June 2026; the events of default under the Series C Convertible Preferred Shares and Senior Secured Convertible Notes (Notes 16 and 19); and the substantial doubt about the Company’s ability to continue as a going concern (Note 2).
Accordingly, Management performed an assessment
as of September 30, 2026. In its assessment, management considered the Kirkman business’s revenue, which was consistent with forecast,
and its gross margin, which improved to
These estimates require significant judgment, including assumptions about future revenue, margins, royalty rates, discount rates and terminal growth rates. It is reasonably possible that these estimates could change materially in the near term. Further declines in sales, the loss of a significant customer, an increase in discount rates, adverse developments relating to the events of default, or a sale of the Kirkman business at a price below its carrying amount could result in impairment charges, which could be material.
15
| 10. | Accounts Payable and Accrued Liabilities |
The Company’s accounts payable consist of obligations that are payable to vendors and other third parties in the normal course of business operations, as well as dividends payable to investors, and its accrued liabilities and accrued compensation are comprised of accrued expenses for consulting, advisory services, professional, audit services and equity awards earned but not yet issued and settlement expense.
| September 30, 2026 |
December 31, 2025 |
|||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Accrued compensation - shares earned but not issued | ||||||||
| Total accounts payable and accrued liabilities | $ | $ | ||||||
| 11. | Lines of Credit |
On August 19, 2025, the Company entered into
two lines of credit agreements with a third-party whereby the Company received a total of $
| September 30, 2026 |
December 31, 2025 |
|||||||
| Line of credit recognized as of January 1 | $ | $ | ||||||
| Proceeds from debt facilities | - | |||||||
| Payments on debt facilities | ( |
) | ( |
) | ||||
| Line of credit as of period end | - | |||||||
| Less: current portion | - | ( |
) | |||||
| Long-term portion | $ | - | $ | - | ||||
| 12. | SBA Loan Payable |
On July 7, 2020, Kirkman applied for and was
granted a thirty (
| September 30, 2026 |
December 31, 2025 |
|||||||
| SBA loan due as of January 1 | $ | $ | ||||||
| Proceeds from SBA loan | - | - | ||||||
| Payments on SBA loan | ( |
) | ( |
) | ||||
| SBA loan due at period end | ||||||||
| Less: current portion | ( |
) | ( |
) | ||||
| Long-term portion | $ | $ | ||||||
16
The Company has the following SBA loan future commitments as of September 30, 2026.
| Amount | ||||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| 2031 and beyond | ||||
| Total | $ | |||
| 13. | Loans Payable, Related Party |
On March 11, 2024, the Company executed a loan
agreement with a related party in the amount of $
On March 10, 2025, the Company executed a loan
agreement with a related party in the amount of $
| September 30, 2026 |
December 31, 2025 |
|||||||
| Loans payable, related party as of January 1 | $ | $ | ||||||
| Loan agreement executed with related party during the periods | - | |||||||
| Reclass to loans payable | - | ( |
) | |||||
| Payments to related party | ( |
) | ( |
) | ||||
| Loans payable, related party as of period end | ||||||||
| Less: current portion | ( |
) | ( |
) | ||||
| Long-term portion | $ | $ | ||||||
| 14. | Loans Payable |
In December 2023, the Company entered into a
short-term debt facility with an officer and director of the parent company, Hemptown Organics Corp., whereby the Company received a non-interest-bearing
loan in the amount of $
On August 29, 2025 the Company entered into
a loan agreement with a third party whereby the Company received approximately $
On November 5, 2025 the Company entered into
a loan agreement with a third party whereby the Company received approximately $
On September 30, 2026, the Company entered into
a loan agreement with a third party whereby the Company received approximately $
| September 30, 2026 |
December 31, 2025 |
|||||||
| Loan payables as of January 1 | $ | $ | ||||||
| Loan agreement executed during the periods | ||||||||
| Reclass to loan payable | - | |||||||
| Payments to loan payable | ( |
) | ( |
) | ||||
| Loan payable as of year-end | ||||||||
| Less: current portion | ( |
) | ( |
) | ||||
| Long-term portion | $ | - | $ | - | ||||
17
| 15. | Derivative Liability |
Series A & B
On November 5, 2025, the Company issued
Revaluation at Period End
The derivative liabilities are remeasured to fair value at each reporting date, with changes in fair value recognized in earnings as follows:
Level 3 Roll-forward
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||
| Series A | Series B | Total | Series A | Series B | Total | |||||||||||||||||||
| Beginning balance | $ | $ | $ | $ | - | $ | - | $ | - | |||||||||||||||
| Initial recognition of derivative liability upon issuance | - | - | - | |||||||||||||||||||||
| Change on revaluation of fair value of derivative liability | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Derecognition upon conversions | - | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||
| Derecognition upon share buybacks | ( |
) | - | ( |
) | ( |
) | - | ( |
) | ||||||||||||||
| Derecognition upon exchange | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Ending balance | $ | - | $ | - | $ | - | $ | $ | $ | |||||||||||||||
The derivative liabilities are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The Company utilized a Monte Carlo simulation model incorporating the following key assumptions at the date of exchange. The Company estimated fair value using a Monte Carlo simulation model, which simulates the Company’s common stock price over the expected term and applies the contractual conversion terms of the Series A and Series B preferred stock. The key assumptions used at the date of exchange and at December 31, 2025 are presented below.
The significant unobservable inputs are expected volatility, expected term and the probability of a dilutive financing. The common stock price, risk-free interest rate and dividend yield are observable inputs.
| Input | At Exchange | 31-Dec-25 | ||||||
| Common stock price | $ | $ | ||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend yield | % | % | ||||||
| Expected term in years | ||||||||
| Probability of dilutive financing | % | % | ||||||
Series C
On March 9, 2026, the Company exchanged all issued and outstanding Series A and Series B preferred stock for Series C Convertible Preferred Stock (the “Series C Preferred”), Senior Secured Convertible Promissory Notes (the “Convertible Notes”) and cash consideration (see Notes 16 and 19). The Series C Preferred is classified as a liability under ASC 480-10-25-14. The embedded conversion features of the Series C Preferred and the Convertible Notes are not clearly and closely related to their host instruments and do not qualify for the scope exception in ASC 815-40. They were therefore bifurcated and recorded as derivative liabilities at fair value on the date of issuance, determined using a Monte Carlo simulation model. The derivative liabilities are presented as a separate line item on the consolidated balance sheet and are remeasured at fair value at each reporting date, with changes in fair value recognized in earnings.
18
Level 3 Roll-forward
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||
| Series C Preferred Stock |
Series C Convertible Note |
Series C Total |
Series C Preferred Stock |
Series C Convertible Note |
Series C Total |
|||||||||||||||||||
| Beginning balance | $ | $ | $ | $ | - | $ | - | $ | - | |||||||||||||||
| Change on revaluation of fair value of derivative liability | ( |
) | - | - | - | |||||||||||||||||||
| Ending balance | $ | $ | $ | $ | - | $ | - | $ | - | |||||||||||||||
The derivative liabilities are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The Company utilized a Monte Carlo simulation model incorporating the following key assumptions as of September 30, 2026:
| Input | September 30, 2026 |
June, 30 2026 |
||||||
| Common stock price | $ | $ | ||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend yield | % | % | ||||||
| Expected term in year | ||||||||
| Probability of dilutive financing | % | % | ||||||
| 16. | Convertible Note |
On March 9, 2026, in connection with the Exchange
and Amendment Agreement (the “Exchange Agreement”) entered into among the Company and the holders of the Company’s Series
A Convertible Preferred Stock and Series B Convertible Preferred Stock, the Company issued senior secured convertible promissory notes
(collectively, the “Notes”) with an aggregate original principal amount of $
Principal Terms of the Notes
The Notes have substantially identical terms.
They mature on August 9, 2027 and bear interest at
Accounting Treatment
The Notes are accounted for as debt under ASC 470 and are subsequently measured at amortized cost using the effective interest method. The embedded conversion feature is not clearly and closely related to the debt host and does not meet the fixed-for-fixed criterion in ASC 815-40. It was therefore bifurcated and recorded as a derivative liability at fair value, determined using a Monte Carlo simulation, and is remeasured at each reporting date, with changes in fair value recognized in other income (expense).
19
Carrying Value and Activity
The following table summarizes the components of the Notes and the related embedded derivative liability as of September 30, 2026:
| Notes Payable |
Embedded Derivative Liability |
|||||||
| Issuance — March 9, 2026 | $ | $ | ||||||
| Conversions | ( |
) | ( |
) | ||||
| Principal adjustments | ||||||||
| Liability with conditional timing consolidation | ||||||||
| Default | - | |||||||
| Change in fair value | - | |||||||
| Balance — September 30, 2026 | $ | $ | ||||||
Pursuant to the Conversion Price Reduction and Waiver agreement dated May 11, 2026, between the Company and the convertible note holders, any cash consideration outstanding as the effective date (as defined in the Exchange Agreement) was consolidated and added to and capitalized as additional principal under each applicable Holder’s existing senior secured convertible promissory note issued pursuant to the Exchange Agreement.
The Notes are presented as current debt on the condensed consolidated balance sheet as of September 30, 2026, as the first scheduled amortization payment is due not more than twelve months after the balance sheet date. The embedded derivative liability is presented within derivative liabilities on the condensed consolidated balance sheet.
For the three and nine months ended September
30, 2026, the Company recognized interest expense of approximately $
Future Principal Payments
The aggregate scheduled principal payments under the Notes as of September 30, 2026 are as follows:
| Year Ending December 31, | Amount | |||
| 2026 | $ | — | ||
| 2027 | ||||
| Total | $ | |||
Fair Value Measurements
The fair value of the bifurcated embedded derivative liability is classified within Level 3 of the fair value hierarchy under ASC 820, as its valuation requires significant unobservable inputs, including expected volatility of the Company’s common stock and probability-weighted estimates of the timing and method of conversion. See Note 13 for measurement details.
| 17. | 2026 Equity Incentive plan |
In May 2026, the shareholder’s’
approved
On June 29, 2026 the Company granted the CEO
20
| 18. | Stock-based Compensation |
The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Awards granted to executives, employees, directors, and non-employees — consisting primarily of restricted stock units (“RSUs”) — are measured at grant-date fair value and recognized as expense in the consolidated statements of operations on a straight-line basis over the requisite service period, with forfeitures recognized as they occur. Awards subject to performance conditions are expensed when achievement of the underlying condition is considered probable, and awards subject to market conditions are expensed over the derived service period regardless of whether the condition is ultimately achieved. Fair value is determined by reference to the closing price of the Company’s common stock on the grant date for awards granted following the Company’s Nasdaq listing, and by reference to the share price established in the most recent Section 409A valuation report prepared by an independent third-party appraiser for awards granted prior to listing.
During the nine months ended September 30, 2026,
and 2025, the Company recorded general and administrative expense of $
| 19. | Common and Preferred Stock |
All shares of Common Stock are entitled to
Preferred Stock
Summary of Significant Transactions
During the nine months ended September 30, 2026, the Company’s capital structure changed significantly as a result of the following transactions:
| ● | Exchange of Series A and Series B Preferred Stock. On March 9, 2026,
the Company exchanged all outstanding Series A and Series B Preferred Stock for Series C Preferred with an aggregate stated value of $ |
| ● | Conversion price
reduction. On May 11, 2026, the Company entered into a Conversion Price Reduction and Waiver Agreement. The agreement reduced the
Series C conversion price to $ |
| ● | Conversions.
Holders converted Series C Preferred with an aggregate stated value of $ |
| ● | Warrant exercise.
A lender exercised warrants to purchase |
As a result of these transactions, common shares
outstanding increased from
Exchange and Amendment Agreement
On March 9, 2026, the Company entered into an Exchange and Amendment Agreement with holders of its outstanding Series A and Series B Preferred Stock. Pursuant to the agreement, the Company exchanged all issued and outstanding Series A and Series B Preferred Stock for a combination of:
| ● | Series C Convertible Preferred Stock (the “Series C Preferred”); |
| ● | Senior Secured Convertible Promissory Notes (the “Convertible Notes”); and |
| ● | Cash consideration. |
21
The transaction resulted in the legal extinguishment of the Series A and Series B Preferred Stock and the issuance of new financial instruments.
Extinguishment of Series A and B Preferred Stock
The Company accounted for the exchange as an extinguishment of the Series A and Series B Preferred Stock. The extinguishment was measured as the difference between:
| ● | The carrying amount of the Series A and Series B Preferred Stock (including associated derivative liabilities), and |
| ● | The fair value of the consideration transferred. |
As a result, the Company recognized a loss on
extinguishment of approximately $
Prior to extinguishment, derivative liabilities associated with the Series A and Series B Preferred Stock were remeasured to fair value, with changes recognized in earnings.
Series C Convertible Preferred Stock
Although the Series C Preferred is legally structured as equity, it represents an obligation to settle a fixed monetary amount through a variable number of shares and is therefore classified as a liability in accordance with ASC 480-10-25-14. Its embedded conversion features are not clearly and closely related to the host instrument and do not qualify for the scope exception for contracts indexed to and settled in the Company’s own stock. They are bifurcated and recognized as derivative liabilities at fair value upon issuance, with subsequent changes in fair value recognized in earnings (see Note 15).
Mandatory Redemption; Covenant Non-Compliance
The Series C is subject to mandatory redemption
(forced amortization) under its Certificate of Designations, in twelve equal monthly installments of $
Events of Default and Related Accounting
Series C mandatory redemption. The Company’s Series C Convertible Preferred Shares (the “Series C”), issued March 9, 2026 and accounted for as a debt host instrument with a bifurcated embedded conversion derivative, are subject to a mandatory redemption provision requiring the Company to begin redeeming the Series C in equal monthly installments beginning on or about June 8, 2026. The Company did not commence the mandatory redemption and made no redemption installment during the three months ended September 30, 2026. The Company has concluded that its failure to commence the mandatory redemption constitutes an Event of Default under the Series C and the Company’s Senior Secured Convertible Notes (the “Notes”), with an event-of-default date of June 8, 2026.
Concurrent listing event of default. Separately, on June 16, 2026 the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination. The failure to maintain a listing on a national securities exchange constitutes a separate and independent Event of Default under the Notes.
22
Effect on the
instruments. As a result of the Events of Default, and from the applicable event-of-default date: (i) the dividend rate on the
Series C increased from
Remedies and status. The Events of Default afford the holders various rights and remedies, including the right to accelerate the Notes and to exercise the default remedies described above. As of the date of this report, no holder had accelerated the Notes or the Series C. The Company is in discussions with the holders.
Convertible Notes
The Convertible Notes are accounted for as debt instruments in accordance with ASC 470. Their embedded conversion features are not clearly and closely related to the debt host and do not qualify for the scope exception for contracts indexed to and settled in the Company’s own stock. They are bifurcated from the host debt instrument and accounted for as derivative liabilities at fair value, with subsequent changes in fair value recognized in earnings (see Note 16).
Common stock
Classification
The Common Stock Consideration Shares (including the portion represented by Blocker Holdback Shares) are classified as permanent equity. Under ASC 480, the shares (i) are not mandatorily redeemable, (ii) carry no obligation for the Company to repurchase its equity, and (iii) do not represent an obligation to issue a variable number of shares — the share count is fixed as of the Exchange Date based on the Market Price determined on that date and does not vary with subsequent changes in fair value, a fixed monetary amount, or movements inversely related to the Company’s shares.
Blocker Holdback Shares are presented within
stockholders’ equity as “Common stock to be issued.” The
The shares were measured at fair value on the Exchange Date based on the quoted market price of the Common Stock (Level 1 of the ASC 820 fair value hierarchy) and included as a component of the consideration transferred in measuring the loss on extinguishment of the Series A and Series B Preferred Stock.
Features
Aggregate shares
Beneficial Ownership Limitation
Issuance is capped at
23
Deferred Cash Consideration
As part of the Exchange and Amendment Agreement
entered into on March 9, 2026, the Company agreed to pay aggregate cash consideration of approximately $
| ● | A total of $ |
| ● | The remaining $ |
On May 11, 2026 the Company and the Note Holders
entered into a Conversion Price Reduction and Waiver Agreement, whereby the remaining $
If the Company does not have sufficient cash to satisfy the full payment at that time, any shortfall is required to be paid in six equal monthly installments.
Accounting Treatment
The Company evaluated this obligation under
ASC 450, Contingencies, and ASC 405, Liabilities and determined that the obligation to pay the remaining $
Presentation
The liability is included within:
| ● | Liability with conditional timing (or current liabilities) as of September 30, 2026. |
Issued Warrants
| Number of warrants |
Weighted-Average Exercise Price per Share |
Weighted-Average Remaining Life |
||||||||||
| Outstanding at December 31, 2025 | $ | |||||||||||
| Granted | - | - | - | |||||||||
| Exercised | ( |
) | - | - | ||||||||
| Outstanding at September 30, 2026 | $ | |||||||||||
| Exercisable at September 30, 2026 | $ | |||||||||||
| Intrinsic value at September 30, 2026 | - | - | - | |||||||||
On March 10, 2025, the Company issued a lender
a warrant for the purchase of
On June 1, 2025, the Company issued a lender
a warrant for the purchase of
On November 5, 2025, the Company issued finder
warrants for the purchase of
On November 17, 2025, the Company issued a lender
a warrant for the purchase of
For the nine months ended September 30, 2026,
the lender exercised
24
| 20. | Segment Reporting |
The Company historically operated through
| (1) | Kirkman, which sold a range of nutraceuticals, supplements and related products; and |
| (2) | HT Naturals, which sold a range of hemp-based consumer products. |
As of March 31, 2026 the Company ceased the operations of HT Naturals and wound down its hemp-based consumer products business. Following the closure, the Company’s continuing operations consist solely of the Kirkman business.
The Company has a corporate function, which is not an operating segment and includes expenses related to corporate management and administration, including legal, audit, accounting, tax, SEC reporting, and investor and public relations, among other corporate expenses.
The Company follows ASC 280, Segment Reporting, as amended by ASU 2023-07. The Company’s chief operating decision maker (the “CODM”) is its Chief Executive Officer.
As a result of the closure of HT Naturals, the CODM reviews financial information and makes operating decisions, including the allocation of resources and the assessment of performance, on a consolidated basis. Accordingly, effective with the closure of HT Naturals during the quarter, the Company has determined that it operates as a single operating segment and a single reportable segment. Prior period segment information has been recast to conform with the current period presentation.
Substantially all of the Company’s long-lived assets are located in the United States, and substantially all of the Company’s revenues are generated from customers located in the United States.
Entity-Wide Disclosures
Geographic Revenue Information
For the nine months ended September 30, 2026
and 2025,
| 21. | Revenue, net |
This table shows revenue by product type:
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Nutraceutical (supplements) | $ | $ | ||||||
| Hemp derived products | ||||||||
| Total revenue by product type | $ | $ | ||||||
As of March 31, 2026, the Company ceased the operations of HT Naturals and wound down its hemp-based consumer products business.
25
| 22. | Concentration |
For the nine months ended September 30, 2026
sales to two customers represented
| 23. | Other Income / (expenses) |
Other expense increased to $
| 24. | Commitments and Contingencies |
The Company has an exclusive license agreement
with Trailer Park Boys Incorporated (“TPB”) to market and sell hemp derived products. This license was effective as of July
21, 2021, expired on
As of September 30, 2026, the Company was engaged
in a contractual dispute with TPB concerning the TPB License. The Company asserts that TPB has not fulfilled certain material obligations
under the TPB License and, as a result, disputes the remaining $
True Health Litigation
On July 14, 2026, the Circuit Court for the
Eighteenth Judicial Circuit, DuPage County, Illinois entered a final order and judgment in favor of the HTO Parties on all counts in the
previously disclosed litigation brought by True Health Medical Center, S.C. (“True Health”), finding that no royalties are
due from the HTO Parties under the royalty agreement. The court entered judgment of $
| 25. | Subsequent Events |
The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the consolidated financial statements were issued. Based on this evaluation, the Company did not identify any subsequent events that would have required recognition or disclosure in the consolidated financial statements.
26
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes and other financial information appearing elsewhere in this Quarterly Report on Form 10-Q. References to “Note” are to the notes included in our unaudited consolidated financial statements appearing elsewhere in this Quarterly Report.
Cautionary note regarding forward looking statements
This report contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “future”, “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this report may include, but are not limited to, statements about:
| ● | our goal and strategies; |
| ● | our future business development, financial condition and results of operations; |
| ● | expected changes in our revenue, costs or expenditures; |
| ● | growth of and competition trends in our industry; |
| ● | our expectations regarding demand for, and market acceptance of, our products; |
| ● | our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate; |
| ● | fluctuations in general economic and business conditions in the markets in which we operate; and |
| ● | relevant government policies and regulations relating to our industry. |
We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate, and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, but these forward-looking statements are not guarantees of future performance or development. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this report, whether as a result of any new information, future events, or otherwise.
There are a number of risks, uncertainties, and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this report, including, among others, those factors set forth in the “Risk Factors” section of our Registration Statement on Form S-1, as amended, and may be subsequently updated by information in future annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Forms 8-K, filed with the Securities and Exchange Commission from time to time.
Overview
Our Company operates in the nutraceutical supplement industry. We are a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, mental clarity and focus, sleep, prenatal and urinary. Our end markets focus on end-consumers through different channels that include pharmacies, U.S. wholesalers, international distributors and direct-to-consumers sales. Our products are sold over the-counter, and consumers do not need a prescription to purchase our products.
27
Results of Operations
Comparison of the Three Months Ended September 30, 2026, to the Three Months Ended September 30, 2025
| Three Months Ended | ||||||||||||||||
| September 30, | Change | |||||||||||||||
| 2026 | 2025 | Amount | Percentage | |||||||||||||
| Statements of Operations | ||||||||||||||||
| Net revenue | $ | 1,645,053 | $ | 1,694,174 | $ | (49,121 | ) | (3 | )% | |||||||
| Cost of goods sold | 684,289 | 715,824 | (31,535 | ) | (4 | )% | ||||||||||
| Gross profit | 960,764 | 978,350 | (17,586 | ) | (2 | )% | ||||||||||
| Sales and marketing expenses | 198,630 | 118,876 | 79,754 | 67 | % | |||||||||||
| General and administrative expenses | 1,076,896 | 937,762 | 139,134 | 15 | % | |||||||||||
| Operating loss | (314,762 | ) | (78,288 | ) | (236,474 | ) | 302 | % | ||||||||
| Other income / (expense) | (399,693 | ) | 337,289 | (736,982 | ) | (219 | )% | |||||||||
| Net loss | $ | (714,455 | ) | $ | 259,001 | $ | (973,456 | ) | (376 | )% | ||||||
Net Revenue
Net revenue for the three months ended September 30, 2026 was $1,645,053 compared to $1,694,174 for the three months ended September 30, 2025 representing a decrease of approximately 3%. This decrease of $49,121 in net revenue was primarily due to an increase in contract manufacturing of $27,004, a decrease in demand from our direct-to-consumer sales channel of $55,588, and a decrease in hemp derived products which was discontinued as of March 31, 2026.
Cost of goods sold
Cost of goods sold for the three months ended September 30, 2026 was $684,289 compared to $715,824 for the three months ended September 30, 2025 representing a decrease of approximately 4%. This decrease of $31,535 in cost of goods was primarily due to a decrease of $62,226 due to a decrease in products primarily sold for contract manufacturing and direct-to-consumer sales channel, decrease of $5,251 due to discontinuation of hemp derived products, an increase in product testing of $26,327, an increase in payroll and employee benefit expenses of approximately $4,012 and an increase in inventory shrinkage and obsolescence of $1,435.
Gross profit
Gross profit for the three months ended September 30, 2026 was $960,764 compared to $978,350 for the three months ended September 30, 2025 representing a decrease of 2%. This decrease of $17,586 was primarily due to a decrease in the demand from our direct-to-consumer sales channel, and discontinuation of sales of our hemp derived products of $76,495, an increase of sales for contract manufacturing of $27,004, and a decrease in cost of goods sold due to products primarily sold for contract manufacturing and the discontinuation of hemp product sales of $67,477, an increase in product testing of $26,327, an increase in payroll and employee benefit expenses of approximately $4,012 and an increase in inventory shrinkage and obsolescence of $1,435.
Sales and marketing expenses
Sales and marketing expenses for the three months ended September 30, 2026, were $198,630 compared to $118,876 for the three months ended September 30, 2025, representing an increase of approximately 67%. This increase of $79,754 was primarily due to an increase in Amazon referral fees of $98,322, an increase in advertising and promotional expenses of $23,173, a decrease in payroll and employee benefit expenses of $36,537, a decrease in professional fees of $11,854, and an increase of $6,783 for conference expenses.
General and administrative expenses
General and administrative expenses for the three months ended September 30, 2026 were $1,076,896, compared to $937,762 for the three months ended September 30, 2025, representing an increase of approximately 15%. This increase of $139,134 was primarily attributable to an increase in payroll and employee benefit expenses of approximately $218,379, an increase in Amazon seller fees of approximately $73,032, an increase in insurance premiums of $58,834, an increase in public company related expenses of $25,271, an increase in computer licenses and dues and subscriptions of 17,869, an increase in rent expense of 21,280, a decrease in professional fees of $230,095, and a decrease in stock-based compensation of $88,499.
28
Other income / (expenses)
Other income / (expense) for the three months ended September 30, 2026 were $399,693 compared to $337,289 for the three months ended September 30, 2025, representing a decrease of approximately 219%. This decrease of $736,982 was primarily due to a decrease in other income which was the result of an Employee Retention Tax Credit (“ERTC”) reimbursement of $419,947, decrease in interest income received of $71,386 which was primarily due to the ERTC, a change of fair value of derivative liability of $154,794, a decrease in change in fair value of derivative liabilities of $154,794, and an increase in interest expense of $90,855.
Comparison of the Nine months Ended September 30, 2026, to the Nine Months Ended September 30, 2025
| Nine Months Ended | ||||||||||||||||
| September 30, | Change | |||||||||||||||
| 2026 | 2025 | Amount | Percentage | |||||||||||||
| Statements of Operations | ||||||||||||||||
| Net revenue | $ | 5,161,125 | $ | 5,116,963 | $ | 44,162 | 1 | % | ||||||||
| Cost of goods sold | 2,118,887 | 2,303,752 | (184,865 | ) | (8 | )% | ||||||||||
| Gross profit | 3,042,238 | 2,813,211 | 229,027 | 8 | % | |||||||||||
| Sales and marketing expenses | 802,721 | 462,545 | 340,176 | 74 | % | |||||||||||
| General and administrative expenses | 4,557,482 | 2,616,489 | 1,940,993 | 74 | % | |||||||||||
| Operating loss | (2,317,965 | ) | (265,823 | ) | (2,052,142 | ) | 772 | % | ||||||||
| Other income / (expense) | (8,017,827 | ) | 171,986 | (8,189,813 | ) | (4762 | )% | |||||||||
| Net loss | $ | (10,335,792 | ) | $ | (93,837 | ) | $ | (10,241,995 | ) | 10915 | % | |||||
Net revenue
Net revenue for the nine months ended September 30, 2026 was $5,161,125 compared to $5,116,963 for the nine months ended September 30, 2025 representing an increase of approximately 1%. This increase of $44,162 in net revenue was primarily due to the increase in the demand from our direct-to-consumer sales channel of $107,342 an increase in contract manufacturing sales of $50,646, and a decrease in hemp derived sales of $114,272 which was discontinued as of March 31, 2026.
Cost of goods sold
Cost of goods sold for the nine months ended September 30, 2026 was $2,118,887 compared to $2,303,752 for the nine months ended September 30, 2025 representing a decrease of approximately 8%. This decrease of $184,865 in cost of goods was primarily due to a decrease in product sales due to the transition of sales from a distributor to direct to consumer of $127,761 and the discontinuation of hemp product sales of $27,194, an increase in product testing of $7,491, an increase in inventory shrinkage and obsolescence of $41,587, an increase in other manufacturing expenses of $13,702, and a decrease in payroll and employee benefit expenses of approximately $95,184 .
Gross profit
Gross profit for the nine months ended September 30, 2026 was $3,042,238 compared to $2,813,211 for the nine months ended September 30, 2025 representing an increase of 8%. This increase of $229,027 was primarily due to the increase in the demand from our direct-to-consumer sales channel of $107,342 an increase in contract manufacturing sales of $50,646, and a decrease in hemp derived product sales of $114,272 which was discontinued as of March 31, 2026, decrease in product sales due to the transition of sales from a distributor to direct to consumer of $127,761 and the discontinuation of hemp product sales of $27,194, an increase in product testing of $7,491, an increase in inventory shrinkage and obsolescence of $41,587, an increase in other manufacturing expenses of $13,702, and a decrease in payroll and employee benefit expenses of approximately $95,184.
Sales and marketing expenses
Sales and marketing expenses for the nine months ended September 30, 2026, were $802,721 compared to $462,545 for the nine months ended September 30, 2025, representing an increase of approximately 74%. This increase of $340,176 was primarily due to an increase in Amazon referral fees of $269,249, an increase in MPG fees of $135,749, an increase in advertising and promotional expenses of $28,202, an increase in professional fees $10,444, an increase in conference expenses of $9,023, and a decrease in payroll and employee benefit expenses of $111,950.
29
General and administrative expenses
General and administrative expenses for the nine months ended September 30, 2026 were $4,557,482 compared to $2,616,489 for the nine months ended September 30, 2025, representing an increase of approximately 74%. This increase of $1,940,993 was primarily attributable to an increase in payroll and employee benefit expenses of approximately $662,565, an increase in Amazon seller fees of approximately $214,300, an increase in insurance premiums of $155,805, an increase in public company related expenses of $157,544, an increase in professional fees of $910,542 increase in computer licenses and dues and subscriptions of $34,140, a decrease in settlement expenses of $50,629.
Other income / (expenses)
Other income /(expenses) for the nine months ended September 30, 2026 and 2025 was $8,017,827 compared to $171,986 representing a decrease of 4762%. This decrease of $8,189,813 was primarily due to a decrease in other income which was the result of an Employee Retention Tax Credit (“ERTC”) reimbursement of $419,947, decrease in interest income received of $64,931 which was primarily due to the ERTC, a loss on issuance of preferred stock of $6,310,464, a change of fair value of derivative liability of $1,097,362, an increase in other expense of $50,000, loss on issuance of preferred stock of $198,705 and an increase in interest expense of $48,353.
Liquidity and Capital Resources
Sources and Uses of Cash for the Nine Months ended September 30, 2026 and 2025
The table below, for the periods indicated, provides selected cash flow information:
| Nine months Ended September 30, 2026 |
Nine months Ended September 30, 2025 |
|||||||
| Net cash (used in) provided by operating activities | $ | (1,018,212 | ) | $ | 1,478,358 | |||
| Net cash used in investing activities | - | (8,512 | ) | |||||
| Net cash used in financing activities | (1,476,584 | ) | (676,164 | ) | ||||
| Net increase (decrease) in cash | $ | (2,494,796 | ) | $ | 793,682 | |||
Source of cash
Cash Flows from Operating Activities
During the nine months ended September 30, 2026, we used $1,018,212 in operating activities as a result of our net loss of $10,335,792, an increase of $304,467 in amortization of right-of-use and intangible assets, $437,973 in stock-based compensation, a change in fair value of derivative liabilities of $1,097,362, loss on issuance of preferred stock of $6,310,464, loss on default of convertible debentures of $198,705, dividends of $77,050, and net changes in operating assets and liabilities of $1,034,245.
During the nine months ended September 30, 2025, our operating activities provided $1,478,358 of cash as a result of our net loss of $93,837, offset primarily by $281,108 in amortization of right-of-use and intangible assets, $598,856 in stock-based compensation, issuance of shares and warrants of $95,893, and net changes in operating assets and liabilities of $571,249.
30
Cash Flows from Investing Activities
During the nine months ended September 30, 2026 and 2025, our investing activities was $0 and $8,512 respectively. In 2025 we used $8,512 in investing activities related to the purchase of property and equipment
Cash Flows from Financing Activities
During the nine months ended September 30, 2026, our financing activities used $1,476,584 of cash proceeds resulting primarily from $450,000 in repayment of liability conditional timing, $32,707 in loan proceeds, $329,002 in repayment of loans, $114,262 in dividend paid, and $616,027 for buyback of series A preferred shares,
During the nine months ended September 30, 2025, our financing activities used $676,164 of cash proceeds resulting primarily of deferred offering costs of $667,810, proceeds from loans and line of credit of $295,012, repayment of loans for $188,366, and payments for payable for acquisition of $115,000.
Letter of Intent
On May 11, 2026, we entered into a binding letter of intent with BullionFx regarding a proposed acquisition of certain intellectual property and related assets.
Under the terms of such letter of intent, the proposed consideration for the acquired assets is expected to consist of convertible preferred stock of the Company with an aggregate stated value of approximately $142.9 million, subject to independent third-party valuation and verification. The preferred stock was expected to automatically convert into shares of our common stock upon receipt of the required stockholder approval. Based on the capitalization assumptions set forth in the letter of intent, following the closing of the proposed transaction and prior to giving effect to any other equity financing, the current stockholders of the Company would own approximately 1.72% of the combined surviving company and the seller would own approximately 98.28% of the combined surviving company.
On June 29, 2026 we received a letter from BullionFX terminating the Letter of Intent.
Amendment
On May 11, 2026, the Company entered into a Conversion Price Reduction and Waiver Agreement with certain holders of the Company’s Series C Convertible Preferred Stock and related senior secured convertible promissory notes. Pursuant to the agreement, the conversion price applicable to the Series C Convertible Preferred Stock during the Fixed Conversion Period was amended to $0.1636 per share of common stock, replacing and superseding the previously applicable Tier 1, Tier 2 and Tier 3 fixed conversion prices and related tier allocation in their entirety.
In addition, pursuant to the agreement, any unpaid cash consideration under the applicable exchange documents as of the effective date of the agreement is to be added to and capitalized as additional principal under each applicable holder’s existing note.
Sources of Cash
On September 30, 2026, the Company entered into a loan agreement with a third party whereby the Company received approximately $32,707. The terms of the loan are for 10 months, with a 7.95% interest rate over the term of the loan.
On November 5, 2025 the Company entered into a loan agreement with a third party whereby the company received approximately $169,048. The terms of the loan are for 10 months, with a 7.0% interest rate over the term of the loan.
On November 4, 2025, Functional Brands Inc. completed a private placement to six institutional investors for gross proceeds of $8,000,000, and net of commissions the Company received proceeds of approximately $7,360,000. In exchange the investors were issued a total of 100,000 Series A preferred shares and 80,000 Series B preferred shares
On August 29, 2025 the Company entered into a loan agreement with a third party whereby the Company received approximately $95,277. The terms of the loan were for 10 months, with a 7.5% interest rate over the term of the loan.
On August 21, 2025, the Company entered into two lines of credit agreements with a third-party whereby the Company received a total of $26,354. The term of the loans were for six months, with a 9% contract interest rate. The loans are to be repaid in Feb 2026.
31
On April 29, 2025, the Company entered into a loan agreement with a third-party whereby the Company received $100,000. The term of the loan is for 1 year with a 22.95% finance charge.
On March 10, 2025, the Company executed a loan agreement with a related party in the amount of $225,000, with an annual interest rate of 18% and a due date of March 7, 2029.
During the nine months ended September 30, 2025 the Company entered into multiple lines of credit agreements with third parties to finance invoices to satisfy multiple vendors of which were repaid during the nine months ended September 30, 2026.
On June 18, 2024, the Company executed a loan agreement with a lender in the amount of $150,000. The payment terms are 12.5% OID, initial principal amount consisting of a $150,000 loan plus $21,500 OID totaling $171,500. In addition, the loan required the Company to issue 37,500 warrants with anti-dilution protection as well as an equity interest in the amount of 2,045 shares of the Company’s stock with reverse split protection through the Senior Exchange Listing. Loan is to mature the earlier of six months from execution, completion of a senior exchange listing of the Company or as mutually agreed, with an interest rate of the higher of 12% or WSJ Prime plus 4% guaranteed.
On March 11, 2024, the Company executed a loan agreement with a related party in the amount of $130,000, with an annual interest rate of 20% and a due date of March 11, 2031.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. Preparing these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. These estimates involve values or conditions that cannot be known with certainty when the financial statements are prepared. Management evaluates its estimates on an ongoing basis, based on historical experience, consultation with experts, and other methods it considers reasonable in the circumstances, as well as its forecasts of how those circumstances may change. Actual results could differ materially from these estimates.
The judgements made in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include:
| ● | Obsolescence of inventories; |
| ● | Recoverability of the carrying value of long-lived assets including property and equipment, and intangible assets; |
| ● | Recoverability of carrying value of goodwill; |
| ● | Discount rate used to calculate present value of future minimum lease payments for right-of-use asset and liabilities; |
| ● | Recognition and measurement of provisions and contingencies; and |
| ● | Valuation of deferred income tax assets. |
Inventories, net
The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions, including forecasted demand compared to quantities on hand, as well as other factors such as potential excess or aged inventories based on product shelf life, and other factors that affect inventory obsolescence. As of December 31, 2025, the inventory reserve was $10,972.
As of September 30, 2026, the allowance for inventory obsolescence decreased $8,765 resulting in a reserve of $2,207
32
Long-Lived Assets
Long-lived assets consist primarily of property and equipment. Long-lived assets are tested for impairment when events and circumstances indicate the assets might be impaired by first comparing the estimated future undiscounted cash flows of the asset or asset group to the carrying value. If the carrying value exceeds the estimated future undiscounted cash flows, an impairment loss is recognized based on the amount that the carrying value exceeds the fair value of the asset or asset group. The Company did not recognize impairment losses during the nine months ended September 30, 2026, and 2025.
Fair Value of Financial Instruments
The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows:
| ● | Level 1 — Observable inputs, such as quoted prices in active markets for identical assets and liabilities. |
| ● | Level 2 — Observable inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
| ● | Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Application within the Company’s Financial Statements
The Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued liabilities, related-party loans, line of credit, government loans, loans payable, convertible debentures (prior to conversion), and warrants issued in connection with financing arrangements. Management believes that, unless otherwise noted, the carrying amounts of these instruments approximate their fair values due to their short-term nature or because they bear interest at market rates.
The following items required fair value measurement or valuation analysis during the periods presented:
| ● | Convertible Debenture |
| ● | Warrants Issued in Financing Transactions |
| ● | Equity Instruments Issued for Services and Financing |
| ● | Business Combination and Intangible Assets (Historical) |
| ● | Financial Instruments Carried at Amortized Cost |
During the three and nine months ended September 30, 2026, the Company primarily applied fair value measurement to equity-linked financing instruments (warrants and stock issued for services), and historically, to convertible debt and business combination accounting. The majority of the Company’s remaining financial instruments are short-term or bear market-rate interest and therefore approximate fair value.
Derivative liabilities
Accounting for Convertible Preferred Stock and Embedded Derivative Liabilities
The Company issued Series A and Series B convertible preferred stock that contain complex conversion features. The accounting for these instruments requires significant judgment in the application of U.S. GAAP, including ASC 480 – Distinguishing Liabilities from Equity, ASC 815 – Derivatives and Hedging, and ASC 820 – Fair Value Measurement. Management evaluates the contractual terms of these instruments to determine the appropriate classification and measurement of the preferred stock and any embedded features.
33
Classification of Preferred Stock
Management evaluates whether preferred stock instruments should be classified as liabilities or equity under ASC 480. Instruments are classified as liabilities if they are mandatorily redeemable, require the issuer to repurchase shares by transferring assets, or obligate the issuer to issue a variable number of shares with a fixed or predominantly fixed monetary value.
The Company’s Series A and Series B preferred stock do not contain mandatory redemption provisions, holder put rights, or other obligations requiring the Company to transfer cash or other assets to the holders. Accordingly, management concluded that the preferred stock represents equity instruments and the host contracts are classified within stockholders’ equity.
Embedded Conversion Features
The preferred stock includes conversion features that allow holders to convert the preferred shares into common stock at variable conversion prices that are subject to market-based adjustments, reset provisions, and anti-dilution protections.
Management evaluates these features under ASC 815 to determine whether they must be separated from the host instrument and accounted for as derivatives. This assessment requires judgment regarding whether the features:
| ● | Meet the definition of a derivative under ASC 815 |
| ● | Are clearly and closely related to the host contract |
| ● | Qualify for equity classification under ASC 815-40 |
The Company concluded that the embedded conversion features meet the definition of derivatives because they are based on the Company’s stock price, involve a notional amount representing the shares issuable upon conversion, require minimal initial investment, and permit net settlement through the issuance of publicly traded shares.
Management further concluded that the conversion features are not clearly and closely related to the equity host instrument and do not qualify for equity classification because the variable conversion pricing and reset mechanisms cause the features to fail the “indexed to the Company’s own stock” requirement under ASC 815-40. Accordingly, the embedded conversion features are bifurcated and recorded separately as derivative liabilities.
Initial Measurement and Allocation of Proceeds
At issuance, the derivative liabilities are measured at fair value. The Company determined the fair value of the embedded conversion features using a Monte Carlo simulation model, which incorporates assumptions regarding expected stock price volatility, expected term, risk-free interest rates, and the impact of contractual reset and floor provisions.
The proceeds received from the issuance of the preferred stock are allocated between the derivative liability and the preferred stock host instrument using the residual method. Under this method, the derivative liability is recorded at fair value and the remaining amount of the proceeds is allocated to the preferred stock. Because the stated value of the preferred shares exceeds the amount allocated to the host instrument, the Company records the difference as a contra-equity discount within stockholders’ equity.
Subsequent Measurement
After initial recognition, the derivative liabilities are remeasured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations. The preferred stock host instrument remains classified within equity and is not subsequently remeasured.
Upon conversion of preferred shares into common stock, the Company derecognizes the associated portion of the derivative liability and adjusts the related equity discount accordingly.
34
Fair Value Measurements and Significant Estimates
The valuation of the derivative liabilities involves the use of significant unobservable inputs and requires substantial management judgment. Key assumptions used in the valuation model include:
| ● | Expected volatility of the Company’s common stock |
| ● | Expected term of the instruments |
| ● | Risk-free interest rates |
| ● | Expected conversion behavior and the impact of contractual reset provisions |
Because these assumptions are not directly observable in the market, the derivative liabilities are classified as Level 3 measurements within the fair value hierarchy under ASC 820.
Changes in these assumptions or market conditions could materially affect the estimated fair value of the derivative liabilities and result in significant non-cash gains or losses in future reporting periods.
Segment Reporting
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires entities to report incremental information about significant segment expenses included in a segment’s profit or loss measure as well as the title and position of the chief operating decision maker (“CODM”). The new standard also requires interim disclosures related to reportable segment profit or loss and assets that had previously only been disclosed annually. The Company adopted ASU 2023-07 effective December 31, 2024 on a retrospective basis.
Income taxes
The Company must exercise judgment in determining the provision for income taxes. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Company recognizes liabilities and contingencies for expected tax audit issues based on the Company’s current understanding of the tax law. For matters where it is probable that an adjustment will be made, the Company records its best estimate of the tax liability including the related interest and penalties in the current tax provision.
In addition, the Company recognizes deferred tax assets relating to tax losses carried forward to the extent there are sufficient taxable temporary differences (deferred tax liabilities) relating to the same taxation authority and the same taxable entity against which the unused tax losses can be utilized. However, utilization of the tax losses also depends on the ability of the taxable entity to satisfy certain tests at the time the losses are recouped.
Events of Default under the Series C Convertible Preferred Shares and Senior Secured Convertible Notes
Overview
During the quarter ended September 30, 2026, the Company was in default under its Series C Convertible Preferred Shares (the “Series C”) and its Senior Secured Convertible Notes (the “Notes”), each issued in the March 9, 2026 exchange transaction. The events of default arose from two independent causes: the Company’s failure to commence the mandatory redemption of the Series C, effective June 8, 2026, and the loss of the Company’s Nasdaq listing on June 16, 2026. The effects of the events of default are reflected in the accompanying financial statements.
Conversion price reduction (May 2026)
On May 11, 2026 — prior to the events of default — the Company entered into a Conversion Price Reduction and Waiver Agreement with certain holders of the Series C and the Notes. The agreement reduced the conversion price applicable to the Series C during the fixed conversion period to $0.1636 per share, superseding the previously applicable tiered fixed conversion prices in their entirety, and provided that any unpaid cash consideration under the exchange documents would be capitalized as additional principal under the applicable holders’ Notes. During the quarter, holders converted Series C with an aggregate stated value of $3,268,000 into common stock at the reduced conversion price, reducing the outstanding stated value of the Series C to $2,764,000 at September 30, 2026 and increasing the number of common shares outstanding.
35
Mandatory redemption
The Series C is subject to a mandatory redemption (forced amortization) provision requiring the Company to begin redeeming the Series C in equal monthly installments of $230,333 beginning on or about June 8, 2026, payable at the Company’s election in cash monthly or in shares of common stock weekly, subject in the case of share settlement to satisfaction of the applicable equity conditions. The Company did not commence the mandatory redemption and made no redemption installment during the quarter or through the date of this report. The Company concluded that this failure constitutes an event of default, effective June 8, 2026. The company has not undertaken mandatory redemption as of September 30, 2026.
Loss of Nasdaq listing
On June 16, 2026, the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination issued June 8, 2026. The failure to maintain a listing on a national securities exchange constitutes a separate and independent event of default under the Notes.
Effect on the Company’s obligations
As a result of the events of default, and effective from the applicable event-of-default date: the dividend rate on the Series C increased from 0% to 24% per annum, recognized as interest expense; the outstanding obligations under the Notes increased to 125% of the amounts otherwise outstanding under the default-premium provisions; interest on the Notes accrues at the 24% default rate; the Company became obligated for a monthly monitoring fee of $5,000; and the conversion price applicable to the Series C and the Notes became the alternate conversion price (85% of the lowest trading price over a ten-trading-day lookback), which increases the number of common shares issuable on conversion and the resulting potential dilution to existing stockholders. Because the events of default give the holders the right to accelerate repayment, the Notes, which were otherwise scheduled to begin amortizing more than twelve months after the balance sheet date, have been reclassified from long-term to current liabilities as of September 30, 2026. The outstanding stated value of the Series C is likewise classified as a current liability.
Impact on results of operations
For the three months ended September 30, 2026, the Company recognized a loss of $714,455 on the change in fair value of its embedded conversion derivative liabilities (a loss of $942,568 for the nine months ended September 30, 2026, reflecting a fair-value gain in the first quarter), included in other income (expense), net. In connection with the events of default, the Company also recognized default-rate interest expense on the Series C and the Notes, a default premium reflecting the increase in the Note obligations to 125%, and monitoring fees. For the nine months ended September 30, 2026, other expense also included a loss of $6,310,464 on the issuance of preferred stock in the March 2026 exchange. General and administrative expenses increased approximately 15% over the prior-year quarter, driven principally by higher payroll, professional fees, and marketplace selling fees. The Company reported a net loss of $10,335,792 for the nine months ended September 30, 2026.
Liquidity and capital resources
At September 30, 2026, the Company had cash of $231,900 and a working capital deficit of $5,804,557, and used $1,018,212 of cash in operating activities during the nine months then ended. The events of default, the resulting acceleration rights and reclassification of the Notes to current liabilities, the mandatory redemption of the remaining $2,764,000 of Series C stated value, and the increased default-rate interest and premium each exceed the Company’s available cash and cash generated from operations, and the Company does not currently have committed financing sufficient to satisfy these obligations as they come due. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to settle redemption and amortization obligations in shares of common stock is constrained by the failure of the applicable equity conditions following the events of default and by limitations on issuances that would require stockholder approval; to the extent obligations are settled in shares at the alternate conversion price, existing stockholders would experience substantial dilution. The Company is in discussions with the holders regarding the terms of the instruments and is evaluating available alternatives, which may include waivers, forbearance, or amendments, restructuring or refinancing, and raising additional capital. As of the date of this report, no holder had accelerated the Notes or the Series C. There can be no assurance that any such alternative will be available on acceptable terms, or at all. See the notes to the financial statements for additional information regarding the events of default and the Company’s going-concern assessment.
36
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and as a result are not required to provide the information required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective due to the existence of the material weaknesses in the Company’s internal control over financial reporting.
Notwithstanding the conclusion by our Chief Executive Officer and Chief Financial Officer that our disclosure controls and procedures as of September 30, 2026 were not effective, and notwithstanding material weaknesses in our internal control over financial reporting, management believes that the unaudited consolidated financial statements and related financial information included in this Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”).
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
37
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
Trailer Park Boys
On November 13, 2025, Trailer Park Boys Inc. (“TPB”) commenced a civil claim against the Company and certain other defendants alleging breach of contract. On February 27, 2026, the Company filed a Statement of Defense denying the allegations advanced by TPB. The Company has also filed a Statement of Counterclaim against TPB asserting claims for breach of contract and negligent misrepresentation in connection with the same agreement. The litigation is at an early stage. The Company intends to vigorously defend the TPB claim and pursue its counterclaim.
True Health
On May 25, 2021, True Health Medical Center, S.C. (“True Health”) amended an existing complaint against Kirkman Group, Inc. (“Kirkman”), James Hall and David Humphrey to assert claims against HTO Nevada, Inc. and HTO Holdings, Inc. (collectively, HTO Nevada, Inc. and HTO Holdings, Inc. are referred to as the “HTO Parties”). Kirkman was the seller of certain assets to the HTO Parties and is a separate legal entity. Affiliates of the HTO Parties were first named in the lawsuit on September 23, 2020.
On July 14, 2026, the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois entered a final order and judgment following a bench trial in the previously disclosed litigation brought by True Health Medical Center, S.C. (“True Health”) against Kirkman Group, Inc. (“Kirkman”), certain individuals, and the HTO Parties. The court entered judgment in favor of the HTO Parties on all counts asserted against them, finding that no royalties are due or owing from the HTO Parties under the royalty agreement. The court determined that the reformulated “981” product is a different product from the “881” product covered by the royalty agreement, and accordingly that no ongoing royalty obligation exists with respect to the 981 product. The court entered judgment against Kirkman, the seller of certain assets to the HTO Parties and a separate legal entity, in the amount of $68,271, consisting of $41,683 in unpaid royalties on sales of the 881 product for the period December 2018 through June 2019 and $26,588 in interest. All claims against the individual defendants were resolved in favor of those defendants, and the case was closed. The time to appeal has not expired, and any party may seek to appeal the judgment. Because no amounts were awarded against the HTO Parties, the Company has not recorded any liability with respect to this matter in the accompanying condensed consolidated financial statements.
Item 1A. Risk Factors
Other than as set forth below, as of the date of this Quarterly Report there have been no material changes with respect to those risk factors previously disclosed in our Annual Report on Form 10-K filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
Our common stock is no longer listed on a national securities exchange and is quoted on the OTC Markets, which may adversely affect the liquidity and market price of our common stock and our ability to raise capital.
Our common stock was removed from listing on The Nasdaq Stock Market and is currently traded on OTC Markets Group Inc. Securities quoted on the OTC Markets generally experience lower trading volumes, wider bid-ask spreads, greater price volatility and less consistent price discovery than securities listed on a national securities exchange. Quotation is dependent on the continued willingness of one or more market makers to publish quotations, and there is no assurance that an active trading market for our common stock will be maintained. Certain institutional investors, mutual funds and other market participants are subject to internal or contractual policies that prohibit or limit investment in securities that are not exchange-listed, and our common stock is no longer eligible for inclusion in indices that require exchange listing. In addition, our common stock may not be eligible for margin lending under Regulation T. Any of the foregoing may reduce demand for our common stock, depress its market price, and make it more difficult and more expensive for us to raise capital or to use our common stock as consideration in acquisitions or in settlement of obligations. These effects may be more pronounced given the substantial doubt about our ability to continue as a going concern described in Note 2 to our condensed consolidated financial statements.
38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
| (a) | Unregistered Sales of Equity Securities |
See Note 18 in the footnotes to the financial statements.
| (b) | Not applicable. |
| (c) | Issuer purchases of equity securities: None. |
Item 3. Default Upon Senior Securities
Series C mandatory redemption. The Company’s Series C Convertible Preferred Shares (the “Series C”), issued March 9, 2026 and accounted for as a debt host instrument with a bifurcated embedded conversion derivative, are subject to a mandatory redemption provision requiring the Company to begin redeeming the Series C in equal monthly installments beginning on or about June 8, 2026. The Company did not commence the mandatory redemption and made no redemption installment during the three months ended September 30, 2026. The Company has concluded that its failure to commence the mandatory redemption constitutes an Event of Default under the Series C and the Company’s Senior Secured Convertible Notes (the “Notes”), with an event-of-default date of June 8, 2026.
Concurrent listing event of default. Separately, on June 16, 2026 the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination. The failure to maintain a listing on a national securities exchange constitutes a separate and independent Event of Default under the Notes.
Effect on the instruments. As a result of the Events of Default, and from the applicable event-of-default date: (i) the dividend rate on the Series C increased from 0% to 24% per annum, which, given the debt classification of the Series C, the Company recognizes as interest expense; (ii) the outstanding obligations under the Notes increased to 125% of the amounts otherwise outstanding under the default-premium provisions; (iii) interest on the Notes accrues at the 24% default rate; (iv) the Company became obligated for a monthly monitoring fee of $5,000; and (v) the conversion price applicable to the Series C and the Notes became the alternate conversion price (85% of the lowest trading price over a ten-trading-day lookback), which the Company reflected in the remeasurement of the embedded conversion derivatives at September 30, 2026.
Remedies and status. The Events of Default afford the holders various rights and remedies, including the right to accelerate the Notes and to exercise the default remedies described above. As of the date of this report, no holder had accelerated the Notes or the Series C. The Company is in discussions with the holders.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
Adoption or Termination of Rule 10b5-1 or non-Rule 10b5-1 Trading Arrangements
During the quarter ended September 30, 2026,
no director or officer
39
Item 6. Exhibits
The following exhibits (listed by number corresponding to the Exhibit Table as Item 601 in Regulation S-K) are filed with this report:
EXHIBIT INDEX
| Exhibit No. | Description | |
| 3.1 | Form (Revised) of Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Share (incorporated by reference to Exhibit 3.8 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 3.2 | Form (Revised) of Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Share (incorporated by reference to Exhibit 3.9 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.1 | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.2 | Form of Amendment to Securities Purchase Agreement (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.3 | Escrow Agreement, dated August 6, 2025 (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.4 | Eighth Amended Forbearance (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.5 | Ninth Amended Forbearance (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 10.6 | Marketing Services Agreement, dated July 23, 2025, between the Company and Outside The Box Capital Inc. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025) | |
| 31.1* | Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2* | Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1** | Certificate of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2** | Certificate of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Filed herewith |
| ** | Furnished herewith. |
40
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Functional Brands Inc. | ||
| Date: November 16, 2026 | By: | /s/ Eric Gripentrog |
| Name: | Eric Gripentrog | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ David R Wells |
| Name: | David R. Wells | |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
41